open access

Vol 67, No 2 (2016)
Original paper
Submitted: 2015-06-11
Accepted: 2015-08-10
Published online: 2016-01-19
Get Citation

The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia

Robert Krysiak, Anna Gdula-Dymek, Bogdan Marek, Bogusław Okopień
DOI: 10.5603/EP.a2016.0021
·
Pubmed: 26884290
·
Endokrynol Pol 2016;67(2):190-196.

open access

Vol 67, No 2 (2016)
Original Paper
Submitted: 2015-06-11
Accepted: 2015-08-10
Published online: 2016-01-19

Abstract

Introduction: Although both statins and fibrates have been found to reduce monocyte cytokine release, no study has investigated whether the effect of hypolipidaemic agents depends on age.

Material and methods: This study retrospectively analysed the results of 65 patients with type 2 diabetes and atherogenic dyslipidaemia, complying with lifestyle intervention, and receiving metformin. These patients were then treated with simvastatin (40 mg daily), micronized fenofibrate (200 mg daily), or simvastatin plus fenofibrate. Tumour necrosis factor-alpha (TNF-alpha), inteleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 (MCP-1) release, as well as circulating levels of high-sensitivity C-reactive protein (hsCRP), were determined separately for patients aged between 20 and 50 years and between 51 and 75 years before the study and after 12 weeks of hypolipidaemic treatment.

Results: Older adults were characterised by higher monocyte release of TNF-alpha and interleukin-6, as well as higher circulating levels of hsCRP, than the younger subjects. The decrease in monocyte release of all investigated cytokines and in plasma hsCRP was similar in both age groups. In turn, the effect of fenofibrate, alone or in combination with simvastatin, on TNF-alpha, interleukin-6, and hsCRP, but not on interleukin-1beta and MCP-1, was stronger in patients aged between 50 and 75 years, and correlated with an improvement in insulin sensitivity only in this age group.

Conclusions: Our results suggest that age may partially determine monocyte-suppressing and systemic anti-inflammatory effects of fenofibrate. (Endokrynol Pol 2016; 67 (2): 190–196)

Abstract

Introduction: Although both statins and fibrates have been found to reduce monocyte cytokine release, no study has investigated whether the effect of hypolipidaemic agents depends on age.

Material and methods: This study retrospectively analysed the results of 65 patients with type 2 diabetes and atherogenic dyslipidaemia, complying with lifestyle intervention, and receiving metformin. These patients were then treated with simvastatin (40 mg daily), micronized fenofibrate (200 mg daily), or simvastatin plus fenofibrate. Tumour necrosis factor-alpha (TNF-alpha), inteleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 (MCP-1) release, as well as circulating levels of high-sensitivity C-reactive protein (hsCRP), were determined separately for patients aged between 20 and 50 years and between 51 and 75 years before the study and after 12 weeks of hypolipidaemic treatment.

Results: Older adults were characterised by higher monocyte release of TNF-alpha and interleukin-6, as well as higher circulating levels of hsCRP, than the younger subjects. The decrease in monocyte release of all investigated cytokines and in plasma hsCRP was similar in both age groups. In turn, the effect of fenofibrate, alone or in combination with simvastatin, on TNF-alpha, interleukin-6, and hsCRP, but not on interleukin-1beta and MCP-1, was stronger in patients aged between 50 and 75 years, and correlated with an improvement in insulin sensitivity only in this age group.

Conclusions: Our results suggest that age may partially determine monocyte-suppressing and systemic anti-inflammatory effects of fenofibrate. (Endokrynol Pol 2016; 67 (2): 190–196)

Get Citation

Keywords

age; simvastatin; fenofibrate; atherogenic dyslipidemia; monocytes; cytokines

About this article
Title

The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia

Journal

Endokrynologia Polska

Issue

Vol 67, No 2 (2016)

Article type

Original paper

Pages

190-196

Published online

2016-01-19

Page views

1765

Article views/downloads

1569

DOI

10.5603/EP.a2016.0021

Pubmed

26884290

Bibliographic record

Endokrynol Pol 2016;67(2):190-196.

Keywords

age
simvastatin
fenofibrate
atherogenic dyslipidemia
monocytes
cytokines

Authors

Robert Krysiak
Anna Gdula-Dymek
Bogdan Marek
Bogusław Okopień

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl